Literature DB >> 11437939

Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi.

M R Hussein1, M Sun, R J Tuthill, E Roggero, J A Monti, E C Sudilovsky, G S Wood, O Sudilovsky.   

Abstract

INTRODUCTION: the length of DNA repetitive sequences (microsatellite instability (MSI)) represent distinct tumorigenic pathways associated with several familial and sporadic tumors.
MATERIAL AND METHODS: To investigate the prevalence and frequency of MSI in melanocytic lesions, the polymerase chain reaction (PCR)-based microsatellite assay was used to examine formalin-fixed, paraffin-embedded tissues of 30 benign melanocytic nevi, 60 melanocytic dysplastic nevi (MDN), and 22 primary vertical growth phase cutaneous malignant melanomas (CMM). Twenty-four microsatellite markers at the 1p, 2p, 3p, 4q and 9p chromosomal regions were used.
RESULTS: MSI was found at 1p and 9p in MDN and CMM but not in benign melanocytic nevi. The overall prevalence of MSI was 17/60 (28%) in MDN and 7/22 (31%) in CMM. The frequency of MSI ranged from 2/24 (9%) to 4/24 (17%) and was most commonly found at D9S162. There was a statistically significant correlation between degree of atypia and frequency of MSI (p<0.001) in MDN. There were two MSI banding patterns: band shifts and additional bands.
CONCLUSIONS: The data presented revealed the presence of low-frequency MSI (MSI-L) at the 1p and 9p regions in both MDN and CMM. Whether the MSI-L pattern reflects a defect in mismatch repair genes is still to be determined.

Entities:  

Mesh:

Year:  2001        PMID: 11437939     DOI: 10.1034/j.1600-0560.2001.280702.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  11 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation.

Authors:  M R Hussein; A K Haemel; O Sudilovsky; G S Wood
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

3.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

Review 4.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 5.  My approach to atypical melanocytic lesions.

Authors:  K S Culpepper; S R Granter; P H McKee
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 6.  [Dysplastic melanocytic nevus].

Authors:  E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 7.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 8.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 9.  Deficient mismatch repair: Read all about it (Review).

Authors:  Susan Richman
Journal:  Int J Oncol       Date:  2015-08-12       Impact factor: 5.650

10.  Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity.

Authors:  Sarantis Gagos; George Papaioannou; Maria Chiourea; Sophie Merk-Loretti; Charles-Edward Jefford; Panagiota Mikou; Irmgard Irminger-Finger; Anna Liossi; Jean-Louis Blouin; Sophie Dahoun
Journal:  Mol Cytogenet       Date:  2008-08-22       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.